Rafarma Pharmaceuticals, Inc. (ORC: RAFA) is pleased to announce acquisition of all outstanding US and Australian patents from Vladislav Laskavy, PhD. The patents that the company has acquired will give the company access to several new technologies including the new generation immune modulator “XR.” The company intends to license XR in Thailand and Malaysia and start offering new revolutionary technologies to patients in Southeast Asia.
Further, to update shareholders on the impact of Coronavirus, Rafarma has not had to lay off or furlough any workers. The company still has more than 20 employees working in various capacities. Some have been repositioned temporarily. “Harvesting and production should continue as planned and we are prepared to weather the temporary economic uncertainty in the global markets. I believe the company will grow even stronger as the global economies recover from this pandemic and I see huge opportunity as countries get back with business as usual” CEO Vladimir Dolgolenko stated.
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
SOURCE: Rafarma Pharmaceuticals, Inc.